...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN-3694 Single Agent Trial Status

This star factory anology is very interesting,  If Zenith epigenetics could sell off each indication molecule for each disease I can only imagine what they could for each one and how many they have

 

IF Zen3694 gets sold separately the value of Zenith IMO is greatly enhanced rather than one large BP buying the entire company and IP for one large price,  If the science is working perfectly this company could be worth a huge amount in a few years!

Share
New Message
Please login to post a reply